Literature DB >> 23796556

Up to 10-year follow-up of the Oxford medial partial knee arthroplasty--695 cases from a single institution.

Per W Kristensen1, Henriette A Holm, Claus Varnum.   

Abstract

Partial knee arthroplasty (PKA) has shown obvious advantages compared to total knee arthroplasty, but survival of PKA from different institutions and registries has differed. In our institution, 695 consecutive Oxford medial PKAs were performed from 2002 to 2011 with mean follow-up of 4.6 years. The overall 10.7-year survival rate was 85.3% (95% CI: 78.7%-90.0%), and no difference in survival for gender and age younger or older than 60 years was found. One year after PKA, 94.3% were very satisfied or satisfied, as were 93.6% six years postoperatively. The revision rate was 7.3% (n=51), and the most common causes for revision were progression of osteoarthritis (n=16), aseptic loosening (n=11), and pain without loosening (n=10). Only 50% of patients revised for pain without loosening had a satisfactory outcome.
Copyright © 2013. Published by Elsevier Inc.

Entities:  

Keywords:  Oxford medial partial knee arthroplasty; causes for revision; patient satisfaction; survival

Mesh:

Year:  2013        PMID: 23796556     DOI: 10.1016/j.arth.2013.05.010

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  11 in total

Review 1.  Larger range of motion and increased return to activity, but higher revision rates following unicompartmental versus total knee arthroplasty in patients under 65: a systematic review.

Authors:  Laura J Kleeblad; Jelle P van der List; Hendrik A Zuiderbaan; Andrew D Pearle
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2017-11-28       Impact factor: 4.342

2.  Tibial component rotation during the unicompartmental knee arthroplasty: is the anterior superior iliac spine an appropriate landmark?

Authors:  Seung-Yup Lee; Suhwoo Chay; Hong-Chul Lim; Ji-Hoon Bae
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2016-06-08       Impact factor: 4.342

3.  [Medial unicondylar knee replacement].

Authors:  O Lorbach; D Pape; P Mosser; D Kohn; K Anagnostakos
Journal:  Orthopade       Date:  2014-10       Impact factor: 1.087

Review 4.  Medial Unicompartmental Osteoarthritis (MUO) of the Knee: Unicompartmental Knee Replacement (UKR) or Total Knee Replacement (TKR).

Authors:  E Carlos Rodriguez-Merchan
Journal:  Arch Bone Jt Surg       Date:  2014-09-15

5.  Revision indications for medial unicompartmental knee arthroplasty: a systematic review.

Authors:  Mei Lin Tay; Sue R McGlashan; A Paul Monk; Simon W Young
Journal:  Arch Orthop Trauma Surg       Date:  2021-02-25       Impact factor: 3.067

6.  Determinants of revision and functional outcome following unicompartmental knee replacement.

Authors:  A D Liddle; A Judge; H Pandit; D W Murray
Journal:  Osteoarthritis Cartilage       Date:  2014-07-17       Impact factor: 6.576

Review 7.  Long-term outcomes of over 8,000 medial Oxford Phase 3 Unicompartmental Knees-a systematic review.

Authors:  Hasan R Mohammad; Louise Strickland; Thomas W Hamilton; David W Murray
Journal:  Acta Orthop       Date:  2017-08-23       Impact factor: 3.717

8.  Bearing Dislocation and Progression of Osteoarthritis After Mobile-bearing Unicompartmental Knee Arthroplasty Vary Between Asian and Western Patients: A Meta-analysis.

Authors:  Kyung-Han Ro; Jae-Won Heo; Dae-Hee Lee
Journal:  Clin Orthop Relat Res       Date:  2018-05       Impact factor: 4.176

9.  The results of Oxford unicompartmental knee arthroplasty in the United States: a mean ten-year survival analysis.

Authors:  R H Emerson; O Alnachoukati; J Barrington; K Ennin
Journal:  Bone Joint J       Date:  2016-10       Impact factor: 5.082

10.  Concentration-Dependent Effects of Cobalt and Chromium Ions on Osteoarthritic Chondrocytes.

Authors:  Christoph Bauer; Christoph Stotter; Vivek Jeyakumar; Eugenia Niculescu-Morzsa; Bojana Simlinger; Manel Rodríguez Ripoll; Thomas Klestil; Friedrich Franek; Stefan Nehrer
Journal:  Cartilage       Date:  2019-11-28       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.